Drug Research
GSK presents positive results from phase III FULFIL study at ERS International Congress
GlaxoSmithKline plc and Innoviva, Inc announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg). in patients with chronic obstructive pulmonary disease...
Drug Research
Boehringer Ingelheim enters research agreement with Saniona
Boehringer Ingelheim, one of the world’s 20 leading pharmaceutical companies, and Saniona, a leading biotech company in the field of ion channel drug discovery, announced that they have entered into a research collaborationwith the objective to discover and develop...
Drug Research
Nymox Pharmaceutical Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results
Nymox Pharmaceutical Corp is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development for enlarged prostate for localized...
Drug Research
Researchers develop safer opioid painkiller from scratch
An international team of researchers - led by scientists at UC San Francisco, Stanford University, the University of North Carolina (UNC), and the Friedrich-Alexander University Erlangen-Nürnberg in Germany has developed a new opioid drug candidate that...
Drug Research
ViiV Healthcare Begins Phase III Programme To Evaluate Two-drug Regimen For HIV-1 Treatment
ViiV Healthcare announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir (Tivicay®) and lamivudine (Epivir®) as a treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy....
Drug Research
Shortage of estrogen drugs in US worries trans women: ‘It’s my peace of mind’
The two most popular injectables used to transition are disappearing from shelves as one awaits re-approval by the FDA, but other factors remain murky The voice on the other the end of the phone had an...
Drug Research
Lupin largest drug maker buys 21 generic brands from Shionogi & Co to strengthen presence in Japanese market
Lupin Ltd, India’s third largest drug maker, will buy a portfolio of 21 generic brands from Osaka-based Shionogi & Co. Ltd at the cost of US $150 million. August 3, 2016: The move will help the company to strengthen. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
